MissionIR Articles
-
MissionIRNewsBreaks – Correlate Energy Corp. (CIPI) Addressing ‘Significant Problem’ with Resilient Energy Solutions
Correlate (OTCQB: CIPI), a tech-enabled development, finance and fulfillment platform for distributed energy solutions across North America, is driving scalability in the microgrid energy distribution market. This follows a new partnership between its subsidiary Distributed Energy Capital (“DEC”) and clean energy development innovator Compass Energy that will establish the United States’ first microgrid utility. “The…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Publishes Q2 2024 Results
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released its financial results for the second quarter ended June 30, 2024 (“Q2 2024”). The company also discussed the clinical development progress of Berubicin, its lead program, and…
-
MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q2 2024 Financial Results, Shares Business Update
Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company today published its financial results for the second quarter ended June 30, 2024, and provided a business update. Scinai plans to host a webinar to discuss…
-
MissionIRNewsBreaks – McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) CEO Showcases Strategic Approach to Industry
McEwen Mining (NYSE: MUX) (TSX: MUX) is an asset-rich diversified gold and silver producer in the Americas. McEwen CEO Rob McEwen recently spoke at the NYC SME’s 9th Annual Current Trends in Mining Finance Conference, where he emphasized the crucial importance of the mining industry to modern civilization and outlined a strategic approach to improving…
-
MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Signs Definitive Loan Restructuring Agreement with EIB Converting Debt into Equity
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the signing of a definitive Loan Restructuring Agreement with the European Investment Bank (“EIB”), its lender. The agreement also included an amendment and restatement to the Finance…
-
MissionIRNewsBreaks – SOBR Safe Inc. (NASDAQ: SOBR) Releases Q2 2024 Quarterly Update
SOBRsafe (NASDAQ: SOBR), a provider of next-generation, transdermal alcohol-detection solutions, is reporting on its NASDAQ listing, financial positioning and sales progress, noting that the NASDAQ Hearings Panel granted the company an exception period continuing the listing of its common stock on the NASDAQ exchange; the company has until Oct. 23, 2024, to regain compliance with…
-
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports on Clinical Data Showing Lead Compound Combined with GLP-1 Agonist Enhances Cognition
Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting preclinical data regarding its lead compound, buntanetap. According to the announcement, the results show the synergistic effect of buntanetap when combined with the glucagon-like peptide 1 (“GLP-1”) agonist dulaglutide (Trulicity[R])…
-
MissionIRNewsBreaks – SenesTech Inc. (NASDAQ: SNES) Schedules Call, Webcast to Report Q2 2024 Financial Results
SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal-pest populations, has announced plans for a conference call and webcast to be held on Aug. 8, 2024, at 5 p.m. ET. According to the announcement, the company plans to release its financial results for second quarter 2024 after market close on the same day.…
-
MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces Conference Call, Webcast to Discuss Q2 Results
HeartBeam(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has scheduled a conference call and webcast to discuss its second-quarter 2024 results. According to the announcement, the call is slated to begin at 4:30 p.m. ET on Aug. 14, 2024. HeartBeam executives, including Branislav Vajdic, CEO and…
-
MissionIRNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Announces Date for Release of Q2 2024 Financial Results
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, will release its financial results for the second quarter of 2024 on Aug. 8, 2024, before the market opens. The financial report will cover the three and six month periods ended June 30, 2024. In addition, the company has scheduled…
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) to Participate as an Anchor Organization at the 2024 Southeastern United States – Canadian Provinces Business Forum
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is participating as an Anchor Organization and panelist at the 2024 Southeastern United States – Canadian Provinces (“SEUS-CP”) Business Forum. The 2024 SEUS-CP is set to take place August 4-6 in Biloxi, Mississippi; Mississippi is home to Mullen’s commercial EV manufacturing. Mullen is a confirmed…
-
MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Long-Term Study Results Confirm Positive Results of Developing Treatment for AD
InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on positive results from a long-term study of INM-901. The in vivo preclinical Alzheimer’s disease (“AD”) involved seven months of dosing and confirms findings from an earlier short-term pilot…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Inks Exclusive License in ‘Transformational’ Step to Treating GBM
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into an exclusive license agreement with Cortice Biosciences Inc. Through the agreement, CNS Pharmaceuticals has acquired a license as well as the intellectual property rights to a…
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Receives Order for Mullen Campus EVs from Leading Transportation and Logistics Company
Mullen Automotive (NASDAQ: MULN), an electric vehicle (“EV”) manufacturer, has received an order for four Mullen Campus electric vehicles from DB Schenker, one of the world’s leading transportation and logistics companies. According to the announcement, the vehicles will be used for mail and delivery on Intel’s technology campus in Chandler, Arizona. The order was received…
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Receives PO from European Distributor for 29 Mullen GOs
Mullen Automotive (NASDAQ: MULN), an electric vehicle (“EV”) manufacturer, has received an order for 29 Mullen GOS from one of its newest European distribution partners. The order for the GOs, which are Mullen’s commercial micro-urban-delivery vehicle, came from GAMA, which is a distribution partner covering southeast Europe, including the Balkans Region. The order from GAMA,…
-
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives US Patent for Methods of Treating Acute Traumatic Brain Injury with Its Lead Drug Candidate
Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent covers methods of treating acute traumatic brain injuries (“TBI”) and preventing nerve cell death with its lead drug candidate, buntanetap. Buntanetap (formerly known…
-
MissionIRNewsBreaks – Mullen Automotive Inc.’s (NASDAQ: MULN) Subsidiary Announces Warranty Coverage for B4 Chassis Cab
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has announced that its subsidiary, Bollinger Motors, released its full warranty coverage on the Bollinger B4 Chassis Cab, the company’s all-new, all-electric Class 4 commercial truck. “We have designed and engineered the Bollinger B4 to have unmatched capability and durability, and we are proud to…
-
MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at the 73rd Emerging Growth Conference
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company is presenting at the 73rd Emerging Growth Conference, scheduled for…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Makes Management Announcement, Plans for Strategic Growth
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is preparing for growth by executing a strategic growth plan. A key element of the plan includes expanding the company’s management team to enable efficient handling of a greater workload of projects and initiatives. With that in mind, the company has named Nelson Cabatuan…
-
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Approval for New Form of Buntanetap
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced receipt of approval from the U.S. Food and Drug Administration (“FDA”) to transition to a new solid form of buntanetap in future clinical trials. “In June 2024, Annovis announced…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Advances The Dream Bowl With Tokenized Autographs, National ESPN+ Broadcast
- MissionIRNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Eyes Increased Adoption of Solutions Across Core Markets
- MissionIRNewsBreaks – Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Leveraging District-Scale Upside in Alaska’s Ambler Mining District
- MissionIRNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Appoints Kasowitz LLP to Strengthen Intellectual Property and Litigation Capabilities
- GlobalTech Corp. (GLTK) Closes Acquisition of Moda in Pelle and Is Redefining Intelligent Retail with AI